Introduction – MASLD in Normal-Weight Individuals Metabolically dysregulated steatotic liver disease (MASLD) is commonly linked with obesity and metabolic syndrome. However, a significant subset of patients develop MASLD despite having a normal body mass index (BMI)—often referred to as lean or normal-weight MASLD.
Introduction – MASLD in Normal-Weight Individuals
Metabolically dysregulated steatotic liver disease (MASLD) is commonly linked with obesity and metabolic syndrome. However, a significant subset of patients develop MASLD despite having a normal body mass index (BMI)—often referred to as lean or normal-weight MASLD. These individuals may still have metabolic abnormalities such as insulin resistance, visceral adiposity, or sedentary lifestyles. Current global MASLD guidelines recommend 3–5% weight reduction even in normal-weight individuals to reduce liver fat. However, emerging evidence suggests that focusing primarily on weight loss in this population may be misguided and clinically impractical.
Why Weight Reduction May Not Help in Lean MASLD
For patients already within a healthy weight range, further weight loss may provide limited metabolic benefit and can be difficult to achieve or sustain. More importantly, exercise exerts powerful liver-specific metabolic effects independent of body weight changes. Physical activity improves insulin sensitivity, enhances mitochondrial function, and increases hepatic fatty acid oxidation—mechanisms that directly reduce liver fat without requiring weight loss. Clinical studies show that structured aerobic or resistance exercise can reduce intrahepatic fat by 10–30%, even when body weight remains unchanged. Meta-analyses confirm that ≥150 minutes of moderate exercise weekly significantly improves hepatic steatosis independent of weight reduction.
These findings suggest that in lean MASLD, lifestyle interventions should prioritise regular physical activity rather than weight-centric goals, reframing exercise as a direct therapeutic strategy rather than merely a tool for weight loss.
Introduction: Chronic hepatitis B (CHB), hepatic steatosis, and type 2 diabetes mellitus (T2DM) frequently coexist, creating a growing clinical challenge. This multinational study evaluated whether T2DM independently influences liver histology in treatment-naïve CHB patients with...
Introduction: Metabolic dysfunction-associated steatohepatitis (MASH) remains a leading cause of cirrhosis, liver failure, and hepatocellular carcinoma, with limited treatment options. This study evaluated DT-109, a novel glycine-based tripeptide, as a gut-targeted therapy aimed at restoring...
Introduction: Metabolic dysfunction-associated steatohepatitis (MASH) remains a leading cause of cirrhosis, liver failure, and hepatocellular carcinoma, with limited treatment options. This study evaluated DT-109, a novel glycine-based tripeptide, as a gut-targeted therapy aimed at restoring...
Introduction: Metabolic dysfunction-associated steatotic liver disease (MASLD) is closely linked to obesity, diabetes, and cardiovascular disease. While both tirzepatide and SGLT2 inhibitors improve metabolic health, comparative real-world data on long-term liver and cardiovascular outcomes have...
Introduction: GLP-1 receptor agonists (GLP-1RAs) have revolutionized obesity treatment, producing substantial weight loss and cardiometabolic benefits. However, many patients discontinue therapy because of cost, adverse effects, or limited access, and weight regain frequently follows. This...
Introduction: The treatment landscape for metabolic dysfunction-associated steatohepatitis (MASH) is evolving rapidly with the emergence of incretin-based therapies. Beyond improving weight and glycemic control, these agents are showing promise in resolving steatohepatitis and slowing fibrosis...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.